Stocks · Financial Services · Shell Companies
Drugs Made In America Acquisition Corp. Ordinary Shares DMAA
$10.89 +0.00% Close, Oct 2, 2026 · NASDAQ · Market cap $264.1M
Expensive vs sectorLow risk
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $0.20, down 99.6% year over year.
- The diluted share count fell 40.0% in a year, mainly through buybacks.
- The stock is in an uptrend: above its 200-day average for 205 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Financial Services sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- EPS growth (TTM, YoY)Bottom 8%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 12%
- Cash conversion (OCF / net income)Bottom 19%
- Accruals (lower is better)Bottom 8%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 21%
- Free-cash-flow yieldBottom 23%
- EBITDA / enterprise valueBottom 11%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 44%
- 6-month returnBottom 45%
- 1-year return vs S&P 500Top 48%
- Distance from 52-week highTop 1%
- Trend checklist (0–4)Top 11%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 6%
- Maximum drawdown, 3 yearsTop 1%
- Beta vs S&P 500 (lower is better)Top 8%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| EPS growth (YoY) | -99.6% | -99.6% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| EPS growth (TTM, YoY) | -99.6% | -99.6% | ↓ | Bottom 8% |
| Return on invested capital | -1.8% | — | Bottom 12% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- -0.05×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 4.4%
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 125.59%
- Shareholder yield
- 125.59%
- Share count change, 1 year
- -40.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 14, 2026).
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 55.5× | — | — | Bottom 21% |
| Free-cash-flow yield | -0.12% | — | — | Bottom 23% |
| Earnings yield | 1.80% | — | — | Bottom 21% |
P/E over the past five years
Range 0.2× – 54.6× since Mar 31, 2025. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +6.1%
- Earnings per share growth (TTM)
- -99.6%
- Change in P/E multiple
- +25881.0%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 249
- Days above the 200-day average
- 205
- 50-day average slope (20 days)
- +0.7%
- 200-day average slope (20 days)
- +0.5%
- Distance from 50-day average
- +1.1%
- Distance from 200-day average
- +2.9%
- RSI (14)
- 86.2
- Relative volume
- 0.00×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 1.7%
- Volatility vs own 5-year history
- 26th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.00
- Correlation with S&P 500
- 0.04
- Current drawdown from 1-year high
- +0.0%
- Maximum drawdown, 3 years
- -0.5%
Financial statements
- Market cap
- $264.1M
- P/E (TTM)
- 55.5
- EPS, diluted (TTM)
- $0.20
- Revenue (TTM)
- $0
- 52-week range
- $10.26 – $10.89
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Gross profit | $0 | $0 |
| Operating income | -$479 | -$2.8M |
| Net income | -$479 | $5.9M |
| EPS (diluted) | -$0.06 | $0.19 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$144,928 | -$279 | $1.3M | $2.3M | $2.2M | $212,958 | $2.0M | $1.7M |
| EPS (diluted) | -$0.01 | -$0.03 | $49.18 | $0.07 | $0.07 | $0.01 | $0.06 | $0.06 |
| FY 2024 | FY 2025 | |
|---|---|---|
| Operating cash flow | -$295 | -$539,187 |
| Capital expenditure | $5 | $0 |
| Free cash flow | -$295 | -$539,187 |
| Dividends paid | $0 | $0 |
| Net share buybacks | -$328,599 | $232.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $20,280
- Total assets
- $146.9M
- Total liabilities
- $9.1M
- Total debt
- $950,000
- Net debt
- $929,720
- Shareholders’ equity
- $137.8M
As of Jun 30, 2026 (filed Aug 14, 2026).
Short interest
- Shares sold short
- 92,523
- Days to cover
- 1.31
- Change vs previous report
- +16.5%
FINRA short interest, settlement date Sep 15, 2026.